Complement-mediated lysis of effector T cells that expressed surface TNF-α, described in rheumatoid arthritis and ankylosing spondylitis patients [50], is unlikely playing a role in our model for our protocol uses de-complemented human serum. Here, TNF is linked to ankylosing spondylitis.